Neurologic impairment In human immunodeficiency virus (HIV) infection may be related to metabolic factors in addition to a direct effect of HIV in the brain. An immune-enhanced tryptophan ca~ tabolism has been described in HIV infected patients that may contribute to neurologic/ psychiatric symptoms. In 41 HIV-infected patients we studied the serum and cerebrospinal fluid concentrations of interferon-y, neopterin, tryptophan and kynurenine in comparison to determinations of neurologic and psychiatric abnormalities as measured by a mental test and computerized tomography. Serum concentrations of interferon-y, neopterin, and kynurenine were increased, whereas tryptophan levels were decreased in patients. Similarly, cerebrospinal fluid concentrations of neopterin and kynurenine were increased in the majority of patients compared to normal values. Significant relations existed between serum neopterin, tryptophan and its degradation product kynurenine and neurologic parameters. In cere~ brospinal fluid , concentrations of neopterin but not of the other parameters tested were related to the mental state of patients. Our study demonstrates that systemic immune activation and its influence on tryptophan metabolism are related to neurologic disease in HIV patients . Intrathecal alterations of tryp~ tophan and kynure nine appear to be less important.
Introduction
Patients with human immunodeficiency virus (HIV ) infection show a progressive loss of im -mune function that is associated with multiple findings of chronic immune activation ( 1 ~3 ), eg: increased neopterin and interferon-y (IFN~y ) (oncentrations in body fluids have been de scribed ::. HIV infection (3, 4) .
Neurologic impairment often de\'elops in :\ ! f h that is related to opportunistic intC:(tl t"[";-~. ,. direct HIV neuronal infection leading: t<l l-i:\ , cephalitis (5) . N eve rtheless , be(au s~ " . Macrophage Figure 1 . Scheme of the association between neopterin production and tryptophan degration induced by interferon-y. The cytokine induces GTP-cyclohydrolase I and consequently neopterin production in human monocytes/ macrophages; in parallel indoleamine (2, 3 )-dioxygenase is activated which degrades trypto phan via the N-formyl -kynurenine pathway to produce kynurenine as a major component.
that an indirect effect of HIV may mediate the neurologic damage by activated cells of the brain like microglial macrophages and by the synthesis , of neurotoxic factors (6) . A role for the disturbed tryptophan metabolism in the pathogenesis of neurologic symptoms has been proposed (7) (8) (9) which is related to the chronic stimulation of macrophages and cytokine production. IFN-y activates indoleamine 2,3-dioxygenase ( IDO ), which causes a degradation of tryptophan forming kynurenine ( Figure. 1 ) and other metabolites (l0 , 11 ) . The calculation of a kynurenine to tryptophan ratio allows an estimate of IDO activity, it represents the quotient of the first product and substrate of the enzyme (8) . The reduced bioavailability of tryptophan for the biosynthesis of serotonin and the accumulation of toxic compounds, such as kynurenic acid and quinolinic acid, as consequence of an enhanced induction of tryptophan catabolism by IFN-y may represent a relevant mechanism of the neurologic disturbances present in HIV infected patients (8) .
In the present work we report on the relationship between serum and cerebrospinal fluid (CSF) concentrations of neoptcrin and IFN-y, the tryptophan m etabolism and indicators of brain damage in patients with different stages of HIV infection. All patients were neurologically examined and underwent cranial computerized tomography (CT ). To test for neurologic destruction we quantified ve ntricular enlargement by measuring the ventricle-brain ratio in the CT. Cognitive functions were assessed by using the structured Interview for the Diagnosis of Al zheimer Dementia and Dementia of other Aetiology (SIDAM) ( 13 ) . It is based on the diagnostic algorithm and criteria for diagnosing dementia according to ICD-10 an DSM-III-R guidelines, it summarizes results of test performance in some different syndrome scales as orientation, m emory, intellectual abilities (such as abstract thinking) and higher cortical functions (such as aphasia or apraxia). The maximal achievable score is 55.
Patients and Methods

Forty
Serum andl or CSF specimen were collected from patients. In total, ' sera of 32 and CSF of 23 patients were available for the study. There were 14 patients of whom matched serum and CSF specimens were available.
Serum and CSF neopterin concentrations were measured using radioimmunoassay ( RIAcid, BRAHMS-Diagnostica, Berlin, Germany ). The detection limit was 1 nmol/I. Normal values (95th percentiles) are below 8.7 nmol/l in serum and below 6 nmol/I in CSF (14).
Tryptophan and kynurenine concentrations were measured by reverse -phase high pressure liquid chromatography as described ( 15) . The normal serum values are 89.2 ± 15 .6 Ilmol/l for tryptophan and 2.1 ± 0.49 Ilmol/l for kynurenine ( 15 ) . The normal kynurenine to tryptophan ratio is 24.4± 7.4 (kynurenine in Ilmol/l divided by tryptophan in Ilmol/l multiplied with 1000). In C SF, normal values of tryptophan are higher than 1 Ilmol/l and of kynurenine below 0.1 Ilmol/l which is the detection limit of the method used.
IFN-y concentrations were quantified by radioimmunoassay (Centocor, Malvern, PA, USA) . The sensitivity of the test was increased by employing an optimized assay procedure ( 3). The detection limit of the test is 18 U I I and the 95th percentile in serum of healthy controls is 100 U I I.
Statistical evaluation of results was done by the non-parametric Wilcoxon rank test. For correlation analyses we used the Spearman rank correlation coefficients.
Results
Seventeen of 32 ( 53%) patients had increased se rum levels of IFN-y, 28/ 32 (87%) had increased neopterin and kynurenine serum concentrations as well and 24/ 32 (75%) patients presented with decreased levels of tryptophan in serum (Table 1 ) . When comparing the subgroups of patients according to the WR stage, serum levels of neopterin were higher (mean ±S .D.: 35.7 ± 19 .3 vs 27.9±16.9 nmol/l, p=O.OOI) and serum tryptophan was lower (43 .7 ± 12 .4 vs 54.3± 16.6 Ilmol/l, p<0.05 ) in patients with WR 6 stage than in patients with WR stage below 5 _ Serum levels of neopterin directly correlated to serum IFN-y (rs=0.524, p<0.005), serum kynurenine concentrations (rs=0.407, p<0.05) and to the serum kynurenine to tryptophan ratio (rs=0.870, p<O.OOO 1 ). They were inversely correlated to serum tryptophan levels (rs=-0.692, p<O.OOOl) . In addition, serum IFN-y was related inversely to se rum tryptophan (rs=-0.525, p<O.OI ) and directly to the kynurenine to tryptophan rati o (rs=0.555 , p<O .OI )_
In eSF, 20 of 23 patients (86%) had increased concentrations of neopterin, 17/ 23 (73%) had increased kynurenine levels and 4 patients ( 17%) showed decreased tryptophan levels . eSF concentrations of neopterin were related to concentrations of try ptophan (rs=0.577, p<O.OI ), kynurenine (rs=0.557, p<O.OI) and the eSF kynurenine to tryptophan ratio (rs =0.411 , p<0.05) . Tryptophan concentrations were related to kynurenine levels (rs=0.717, p<O.OOl).
In examining correlations betwee n serum and eSF parameters, serum neopterin was related to the eSF kynurenine to tryptophan ratio (rs=0 .533 , p<0.05). No other significant correlations were found across the blood/ brain barrier.
The relations between neuropsyc hiatric abnormalities and the serum values of IFN -y, neopterin, tryptophan and serum kynurenine to tryptophan ratio are shown in Table 2 . Serum neopterin (Figure_ 2 ) and the serum kynurenine to tryptophan ratio were inversely related to the SIDAM score reflecting cognitive impairment and directly to ventricle brain ratio in eT ,which monitors the size of brain lesions , Serum tryptophan was directly related to SIDAM ( Figure. 2 ) and inversely to ventricle brain ratio . No significant correlations of serum kynure nine existed with SIDAM or ventricle brain rati o. In eSF, neopterin was inversely related to the SIDAM score ( rs=-0.470, p<0 .05) . No o ther relations were found between neurologic parameters and eSF determinations.
In the subgroup of 14 patients of whom both, serum and eSF, determinations were available, si milar associations were found: serum neopterin was significantly related to SIDAM (rs=-0 .568 , p <0_05 ) and to the ventricle brain ratio (rs=0.613, p<0.03) . The association between serum tryptophan and neurologic evaluations did not reach statistical significance . CSF values of neopterin and tryptophan were not related to SIDAM o r eT measurement. 
Discussion
Increased serum neopterin concentrations which were detected in the majority of our HIV patients indicate enhanced immune activation and concomittant endogenous formation of IFN-y, because neopterin is released in large amounts by monocyte/macrophages upon stimulation with IFN-y (16). In fact, IFN-y concentrations were increased to a lesser frequency in our group of patients than neopterin, probably because IFN-y is rapidly cleared from plasma and circulating concentrations do not fully correspond to .the actual amount of the cytokine released. In addition, oth-.. . er . cytokines such as TNF-a are known to further enhance the effect of IFN -yon the macrophages regarding neopterin production in vitro. A close relationship between the IFN -y, TNF-a and neopterin system was recently demonstrated also in vivo, when associations between soluble receptors for TNF-a, neopterin and IFN-y have been shown in HIV infection and in other diseases (17, 18) . These findings agree well with the chronic immune activation state present in HIVinkction (5, 18, 19) . Diminished tryptophan concentrations and increased kynurenine levels in serum argue in favour of an accelerated tryptophan catabolism in HIV patients. Kynurenine is a metabolite of the tryptophan degradation pathway. This metabolic process is catalyzed by the IDO and leads, in a first step, to the production of N -formyl-kynurenine ( Figure. 1) , further products include quinolinic acid. In chronic immune activation states, such as congestive heart failure (20), Lyme neuroborreliosis (15) , HIV infection (21) and mul-tiple sclerosis (22) an enhanced tryptophan catabolism has been described that is further supported by our study. Enhanced concentrations of kynurenine found in the patients with decreased tryptophan levels confirm that low tryptophan is not due to reduced dietary intake of the essential amino acid.
The correlations found in serum between IFNy and neopterin concentrations on the one hand, and the diminished tryptophan levels, increased kynurenine levels and increased kynurenine to tryptophan ratio on the other hand, confirm the relationship between chronic immune activation and enhanced tryptophan catabolism in HIV infection. In vitro, the induction of IDO and, consequently, the metabolism of tryptophan, is triggered by IFN-y (10) . In vivo, the activation of IDO can be estimated by the kynurenine to tryptophan ratio. Therefore, as previously described, in HIV patients the tryptophan degradation is related to the chronic enhancement of immune activation in patients (23) . Increased levels of neopterin and kynurenine and the correlations between neopterin and the products of tryptophan catabolism in the CSF provide further support for the conclusions drawn from serum data to be true also in the local compartment of the central nervous system.
The parameters used in our study to measure the neurologic and psychiatric impairment in patients with HIV infection were related to serum markers of immune activation and to indicators of enhanced tryptophan degradation. The mechanisms involved in the neurologic dysfunction of HIV infected patients may include a reduced availability of 5-hydroxytryptamine (serotonin or 5-HT, Ref ... 7, 8) or the accumulation of neurotoxins such as kynurenic acid and quinolinic acid (8, 11 ) . Both circumstances would result from an exaggerated tryptophan catabolism . Therefore, the present study is consistent on the one hand with an involvement of the tryptophan metabolites in the HIV -associated neurologic symptoms and on the other hand with the responsibility of chronic immune stimulation in the development of this mechanism. The association found between the size of brain lesions, quantified by CT as ventricle/ brain-ratios, and neopterin levels indicates that activated immunocompetent cells like macrophages and Tlymphocytes could be involved in the destruction of cerebral tissue. However, a correlation not necessarily indicates a cause-effect relationship.
Interestingly, the presence of increased amounts of neopterin itself could have a role in the immunopathogenesis of brain lesions, because recently it has been shown that neopterin is capable of enhancing radical-mediated cytotoxic mechanisms (24) . Thus, cellular CytotoXICIty of immunocompetent cells within the brain might be enhanced in the presence of increased amounts of neopterin.
Noteworthy, the results in CSF are less conclusive. Only neopterin concentrations were related to the SIDAM score. It appears that the systemic chronic immune stimulation in HIV infection is more related to the tryptophan metabolism and the neurologic damage than local CNS phenomena. Although a protagonism has been proposed for activated brain macrophages in the secretion of neurotoxic products (6) our data point towards a more relevant role for systhemic metabolic disturbances on the origin of HIV-associated neurologic impairment which is probably in addition to local effects of HIV on brain tissue.
Unfortunately, the number of patients with matched serum and CSF specimens was rather low in this study. However, the evaluation of the 14 patients with matched material confirms the results obtained from the whole set of data, Certainly, a larger series of matched samples will be perferablc for final conclusions.
